We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
+9.75%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$135M
AUM Growth
-$1.28M
(-0.95%)
Cap. Flow
-$11.4M
Cap. Flow
% of AUM
-8.5%
Top 10 Holdings %
Top 10 Hldgs %
21.49%
Holding
245
New
28
Increased
29
Reduced
140
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$2.85M |
| 2 |
Alphatec Holdings
ATEC
|
+$2.84M |
| 3 |
Indivior Pharmaceuticals
INDV
|
+$2.84M |
| 4 |
Neurocrine Biosciences
NBIX
|
+$2.12M |
| 5 |
APLS
Apellis Pharmaceuticals
APLS
|
+$1.76M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioCryst Pharmaceuticals
BCRX
|
+$4.17M |
| 2 |
Pacira BioSciences
PCRX
|
+$3.36M |
| 3 |
Pfizer
PFE
|
+$3.06M |
| 4 |
United Therapeutics
UTHR
|
+$2.79M |
| 5 |
uniQure
QURE
|
+$2.06M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 57.92% |
| 2 | Real Estate | 14.45% |
| 3 | Financials | 7.05% |
| 4 | Industrials | 3.2% |
| 5 | Technology | 2.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Rithm Capital
RITM
$5.2B
| $4.32M | 3.21% |
380,966
| – | – |
|
2
Harmony Biosciences
HRMY
$1.96B
| $3.88M | 2.88% |
97,000
-25,000
| -20% | -$878K |
|
|
LKFT
3
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
| $3.12M | 2.32% |
108,500
| – | – |
|
|
4
Merck
MRK
$315B
| $2.73M | 2.03% |
+24,000
| New | +$2.85M |
|
|
EFC
5
Ellington Financial
EFC
$1.7B
| $2.6M | 1.93% |
201,602
| – | – |
|
|
6
Neurocrine Biosciences
NBIX
$17.2B
| $2.59M | 1.93% |
22,500
+15,500
| +221% | +$2.12M |
|
7
MGIC Investment
MTG
$6.23B
| $2.54M | 1.89% |
99,379
-15,000
| -13% | -$361K |
|
8
argenx
ARGX
$53.8B
| $2.44M | 1.81% |
4,500
-2,750
| -38% | -$1.39M |
|
|
9
Indivior Pharmaceuticals
INDV
$4.79B
| $2.36M | 1.76% |
+242,500
| New | +$2.84M |
|
|
DX
10
Dynex Capital
DX
$2.87B
| $2.32M | 1.72% |
181,492
| – | – |
|
11
BioMarin Pharmaceuticals
BMRN
$11.5B
| $2.28M | 1.7% |
32,500
+16,000
| +97% | +$1.34M |
|
12
Sarepta Therapeutics
SRPT
$1.82B
| $2.25M | 1.67% |
18,000
+10,500
| +140% | +$1.45M |
|
|
DVAX
13
DELISTED
Dynavax Technologies
DVAX
| $2.24M | 1.67% |
201,500
+71,500
| +55% | +$788K |
|
|
14
United Therapeutics
UTHR
$22.7B
| $2.24M | 1.67% |
6,250
-8,250
| -57% | -$2.79M |
|
|
RWT
15
Redwood Trust
RWT
$641M
| $2.23M | 1.66% |
288,343
| – | – |
|
|
FOLD
16
DELISTED
Amicus Therapeutics
FOLD
| $2.19M | 1.63% |
205,000
+2,500
| +1% | +$27.2K |
|
|
MFA
17
MFA Financial
MFA
$960M
| $2.13M | 1.59% |
167,725
| – | – |
|
|
18
Alphatec Holdings
ATEC
$1.31B
| $2.06M | 1.53% |
+370,000
| New | +$2.84M |
|
|
EXAS
19
DELISTED
Exact Sciences
EXAS
| $2.04M | 1.52% |
30,000
| – | – |
|
20
Invesco QQQ Trust
QQQ
$466B
| $2.04M | 1.52% |
4,182
+925
| +28% | +$438K |
|
21
Invesco NASDAQ 100 ETF
QQQM
$96.3B
| $2.04M | 1.52% |
10,158
+2,259
| +29% | +$440K |
|
22
Royalty Pharma
RPRX
$25.8B
| $1.91M | 1.42% |
67,500
+7,500
| +13% | +$208K |
|
23
Mirum Pharmaceuticals
MIRM
$7.25B
| $1.75M | 1.3% |
45,000
-19,000
| -30% | -$758K |
|
24
Jazz Pharmaceuticals
JAZZ
$15.5B
| $1.73M | 1.28% |
15,500
+4,500
| +41% | +$493K |
|
|
MITT
25
TPG Mortgage Investment Trust
MITT
$243M
| $1.57M | 1.17% |
208,879
| – | – |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q3 2024 Portfolio in Review
As of Q3 2024, AlphaCentric Advisors held 245 positions worth $135M, down 0.95% from $136M the previous quarter. Its ten largest holdings account for 21% of the portfolio.
AlphaCentric Advisors withdrew a net $11.4M in Q3 2024, closing 15 positions and reducing 140 holdings. Its most notable exit was BioCryst Pharmaceuticals, an estimated $4.17M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 60% a quarter earlier, followed by Real Estate and Financials.
Against the trend, AlphaCentric Advisors opened a new position in Merck worth $2.73M.
- AlphaCentric Advisors's largest Q3 2024 buy was Merck: 24,000 shares worth $2.73M.
- AlphaCentric Advisors added most to Neurocrine Biosciences in Q3 2024, an estimated $2.12M increase.
- AlphaCentric Advisors's biggest Q3 2024 reduction was Pfizer, cutting an estimated $3.06M.
- AlphaCentric Advisors fully exited BioCryst Pharmaceuticals in Q3 2024, selling an estimated $4.17M.
- AlphaCentric Advisors's ten largest holdings make up 21% of its $135M portfolio in Q3 2024.
- AlphaCentric Advisors opened 28 new positions and closed 15 in Q3 2024.
- AlphaCentric Advisors's portfolio value fell 0.95% quarter-over-quarter to $135M.
Based on AlphaCentric Advisors's 13F filing for Q3 2024, filed 30 Oct 2024.